Decreased susceptibility to noncarbapenem antimicrobials in extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates in Toronto, Canada

18Citations
Citations of this article
39Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Retrospective review from 11 Canadian hospitals showed increasing incidence of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae from 0.12 per 1,000 inpatient days during 2005 to 0.47 per 1,000 inpatient days during 2009. By 2009, susceptibility rates of ESBL-positive E. coli/K. pneumoniae were as follows: ciprofloxacin, 12.8%/9.0%; TMP/SMX, 32.9%/12.2%; and nitrofurantoin, 83.8%/10.3%. Nosocomial and nonnosocomial ESBL-producing E. coli isolates had similar susceptibility profiles, while nonnosocomial ESBL-producing K. pneumoniae was associated with decreased ciprofloxacin (P = 0.03) and nitrofurantoin (P < 0.001) susceptibilities. Copyright © 2012, American Society for Microbiology. All Rights Reserved.

Cite

CITATION STYLE

APA

Lowe, C. F., McGeer, A., Muller, M. P., & Katz, K. (2012). Decreased susceptibility to noncarbapenem antimicrobials in extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates in Toronto, Canada. Antimicrobial Agents and Chemotherapy, 56(7), 3977–3980. https://doi.org/10.1128/AAC.00260-12

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free